Metrics as of 10/15/2026, 09:05 AM (Berlin time), refresh in progress.
GMR Solutions Inc.
GMR Solutions Inc., headquartered in Lewisville, Texas, is a leading U.S.-based company specializing in comprehensive out-of-hospital healthcare and mobile clinical services. The organization delivers both emergency and non-emergency medical care. Beyond direct patient transport and treatment, their service portfolio…
1D
+1.2%
1W
+6.2%
1M
-19.2%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
Not enough history for an assessment
PRICE TARGET LOW
US$14.00
CONSENSUS
US$19.67
MEDIAN
US$19.00
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 11/09/2026
P/E
7.39
P/B
0.73
EV/EBITDA
10.81
RETURN ON EQUITY
-3.6%
NET MARGIN
-1.9%
DEBT/EQUITY
6.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
63.6%
FLOAT SHARES
34,376,313
AVG. DAILY VOLUME (30D)
1,115,799
Van Horne Edward
Jacoba Lisa
Jacoba Lisa
Loporcaro Nicola
Tierney Brian Scott
GMR Solutions Inc. is a company in the Healthcare sector, Medical - Care Facilities industry, headquartered in United States.
The CEO is Nicola Loporcaro, the company employs around 34,000 people.
The IPO was on 12/05/2026; the stock trades on NYSE under the ticker GMRS.
1 analysts rate the stock, the consensus is Buy (as of 11/09/2026).
The average price target is US$19.67, ranging from US$14.00 to US$30.00, with a median of US$19.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 09/11/2026.
No, GMR Solutions currently does not pay a dividend.
Comparable stocks include HCA Healthcare, Tenet Healthcare, DaVita, Universal Health Services, Hims & Hers Health, LifeStance Health Group, Concentra Group Holdings Parent and Acadia Healthcare Company.
Clicking "Analyze stock" lets five strategies assess GMR Solutions against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.